ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2009
Kidney pathological changes in metabolic syndrome: a cross-sectional study.
Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 108 citations in OpenAlex.
- Machine learning-based prediction of tubulointerstitial lesions in diabetic kidney disease: a multicenter validation study.Renal failure · 2025Article
- Post-transplantation management of hyperparathyroidism and its association with kidney graft survival and fibrosis.Clinical and experimental nephrology · 2025Article
- The Role of Comorbidities in COVID-19 Severity.Viruses · 2025Observational
- Association of changes in metabolic syndrome with new-onset and progression of chronic kidney disease.Endocrine · 2025Article
- Analysis of the impact of obesity on the prognosis of IgA nephropathy according to renal function and sex.Clinical and experimental nephrology · 2024Article
- 8-Aminoguanine and its actions in the metabolic syndrome.Scientific reports · 2024Article
- The Metabolic Syndrome, a Human Disease.International journal of molecular sciences · 2024Review
- Associations Between Life's Essential 8 and Chronic Kidney Disease.Journal of the American Heart Association · 2023Article
- Metabolic phenotypes and risk of end-stage kidney disease in patients with type 2 diabetes.Frontiers in endocrinology · 2023Article
- Review
- Acute kidney injury and the compensation of kidney function after nephrectomy in living donation.World journal of transplantation · 2022Review
- Prognostic value of metabolic syndrome in renal structural changes in type 2 diabetes.International urology and nephrology · 2022Article
- Association of metabolic syndrome traits with urinary biomarkers in Japanese adults.Diabetology & metabolic syndrome · 2022Article
- Activation of angiotensin-converting enzyme 2 ameliorates metabolic syndrome-induced renal damage in rats by renal TLR4 and nuclear transcription factor κB downregulation.Frontiers in medicine · 2022Article
- The Complement System in Metabolic-Associated Kidney Diseases.Frontiers in immunology · 2022Review
- Metabolic Syndrome-Related Kidney Injury: A Review and Update.Frontiers in endocrinology · 2022Review
- Impact of Obesity in Kidney Diseases.Nutrients · 2021Review
- Effects of metabolic syndrome on renal function after radical nephrectomy in patients with renal cell carcinoma.International urology and nephrology · 2021Article
- The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease.Kidney international reports · 2021Article
- Larger Nephron Size and Nephrosclerosis Predict Progressive CKD and Mortality after Radical Nephrectomy for Tumor and Independent of Kidney Function.Journal of the American Society of Nephrology : JASN · 2020Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe worldwide prevalence of metabolic syndrome is increasing and has been associated with chronic kidney disease. Kidney pathological findings in patients with metabolic syndrome have not been well described, as was explored in this study. STUDY
designCross-sectional study. SETTING &
participantsWe retrospectively screened clinical information for 146 patients who underwent elective nephrectomy for renal cell carcinoma between January 2005 and March 2007 at Brigham and Women's Hospital, Boston, MA. Twelve patients with metabolic syndrome were identified. Twelve age- and sex-matched patients who did not have any of the criteria for metabolic syndrome were used as controls. PREDICTOR: Presence of metabolic syndrome defined by using Adult Treatment Panel III criteria. OUTCOMES: Histological characteristics in each group, decrease in kidney function at 1-year follow-up. MEASUREMENTS: Two pathologists blinded to the clinical diagnosis independently evaluated nephrectomy specimens using Banff criteria to objectively assess histological characteristics.
resultsBaseline characteristics were similar between the 2 groups. On histopathologic examination, patients with metabolic syndrome compared with controls had a greater prevalence of tubular atrophy (P = 0.006), interstitial fibrosis (P = 0.001), and arterial sclerosis (P = 0.001), suggesting microvascular disease. Patients with metabolic syndrome had greater global (P = 0.04) and segmental glomerulosclerosis (P = 0.05). Glomerular volume and cross-sectional surface area were not different. The combined end point of tubular atrophy greater than 5%, interstitial fibrosis greater than 5%, and presence of arterial sclerosis was more prevalent in patients with metabolic syndrome (P = 0.003; odds ratio, 33; confidence interval, 2.9 to 374.3) than controls. After 1 year, estimated glomerular filtration rate was significantly lower in patients with metabolic syndrome compared with controls (P = 0.03). LIMITATIONS: Small sample size, retrospective design.
conclusionsWe report a high prevalence of microvascular disease in patients with metabolic syndrome. There was a steeper decrease in kidney function over time in patients with metabolic syndrome, suggesting limited renal reserve. Aggressive screening and management may be warranted in patients with metabolic syndrome to protect kidney function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.